NovaBay Pharmaceuticals (NYSE:NBY) Earns Hold Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued on Wednesday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets cut their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating for the company in a report on Monday, November 11th.

NovaBay Pharmaceuticals Trading Up 1.0 %

NYSE:NBY opened at $0.60 on Wednesday. The stock has a 50-day moving average price of $0.65 and a 200 day moving average price of $1.22. The stock has a market capitalization of $2.94 million, a P/E ratio of -0.01 and a beta of 0.69. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $10.23.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.